Ctc Bio

CTC Bio is a KOSDAQ-listed pharmaceutical and bio company organized around two business pillars: animal health products and human pharmaceuticals.

The company operates five domestic production sites and two research centers, using microbial fermentation, drug coating, and delivery technologies to manufacture feed additives, injectables, vaccines, improved new drugs, and generics.

The animal health segment consists of feed additives, disinfectants, and vaccines, with flagship products including CTCZYME, a feed digestive enzyme that was the first in Asia to receive FDA approval, and Bacter Phase, described as the world's first next-generation antibiotic-alternative feed additive.

CTCZYME is exported to 32 countries including those in Latin America and Canada, and the product targets specific bacteria to reduce issues of resistance and residue in animals. Production takes place at GMP-certified plants in Hwaseong, Gyeonggi Province, and Hongcheon, Gangwon Province.

The human pharmaceuticals segment consists of improved new drugs, generics, and health functional foods, with a flagship product called ONE-TOO tablet, a combination drug pairing the premature ejaculation ingredient clomipramine with the erectile dysfunction ingredient sildenafil.

The animal health segment's revenue fell from KRW 75.2 billion in 2022 to KRW 62.8 billion in 2024, reflecting weakness in both domestic and export sales.

At the end of October 2025, the largest shareholder changed from Pharma Research to Bionote, an animal diagnostics specialist, shifting the company from co-management to sole management, with the controlling figure behind both Bionote and affiliated SDB Investment being SD Biosensor chairman Cho Young-sik.

Consolidated revenue in 2025 was KRW 123.77 billion, down about 14.3% from KRW 144.41 billion in 2024, while operating profit turned positive at KRW 6.25 billion, reversing consecutive losses of KRW 3.95 billion in 2024 and KRW 4.58 billion in 2023.

Net profit attributable to controlling shareholders also recovered to KRW 3.24 billion in 2025, moving away from a large loss of KRW 15.59 billion in 2023 and KRW 5.22 billion in 2024.

The fact that the 2023 net loss (KRW 15.59 billion) was far larger than the operating loss (KRW 4.58 billion) suggests a significant one-off item below the operating line that year.

On a quarterly basis, revenue fell sharply to KRW 22.64 billion in the third quarter of 2025 from KRW 35.42 billion in the prior quarter, then recovered to KRW 31.62 billion in the fourth quarter, KRW 34.44 billion in the first quarter of 2026, and KRW 33.69 billion in the second quarter of 2026.

The operating margin also jumped from 6.9% in the third quarter of 2025 and 4.8% in the fourth quarter to 13.3% in the first quarter of 2026 and 11.3% in the second quarter, marking two consecutive quarters of double-digit margins.

The company attributed the improvement to a larger share of high-margin overseas product sales and greater production and cost efficiency.

Combined net profit attributable to controlling shareholders over the most recent four quarters (Q3 2025 through Q2 2026) totaled KRW 7.51 billion, showing an improved run-rate compared with full-year 2025.

Still, revenue itself remains more than 25% below the 2022 level of KRW 165.21 billion, meaning the return to profit has so far come from margin improvement rather than a recovery in overall scale.

The animal health and feed additive market that CTC Bio operates in is a moderately growing sector, with the global companion animal drugs market projected to grow at roughly a 5.3% compound annual rate over the coming years.

However, the market is led by large global animal healthcare companies such as Zoetis, Merck, Boehringer Ingelheim, and Virbac, meaning a small to mid-sized domestic player like CTC Bio competes mainly through technical differentiation in specific product categories such as enzymes and antibiotic alternatives.

Domestic distribution of animal medicines depends heavily on sales networks through feed companies, animal hospitals, and distributors, and the company's animal health sales workforce has reportedly been relatively limited in scale.

In the human pharmaceuticals segment, within a domestic competitive landscape centered on improved new drugs and generics, the company has sought differentiation through niche products such as its combination premature ejaculation treatment, though the domestic market size is modest and expanding prescriptions at large hospitals takes time.

In April 2026, the company's sales performance in the Korean market was recognized by global chemical company BASF, which awarded it two prizes for 2025 Record Sales Growth and 2025 Long-term Partnership, externally confirming its credibility as a raw-material supply chain partner.

This can be interpreted as evidence of a stable position within overseas raw-material sourcing and distribution channels.

With the recent change in controlling shareholder to animal diagnostics specialist Bionote, industry attention has turned to potential synergies linking diagnostics and treatment within the animal healthcare value chain.

In its first-quarter 2026 earnings announcement, the company stated that the improvement was not a temporary factor but the result of structural improvement and business portfolio transformation, and that it plans to pursue mid- to long-term growth through expanding overseas market share, focusing on high-value-added products, and strengthening production efficiency and cost competitiveness.

In the animal health segment, there were reports that the company is pursuing a supply deal for CTCZYME with CP Group, the largest grain company in Southeast Asia, with a stated target of delivery within the year, though no further disclosure on progress has been confirmed since.

In April 2026, the company won two awards at a BASF Asia-Pacific partner event, externally confirming its performance in the raw-material distribution business, which can be seen as a marker of progress in its overseas expansion strategy.

On the governance side, since the change of controlling shareholder to Bionote in October 2025, a sole management structure has been settling in, and how business linkages with the animal diagnostics specialist will materialize remains a point to watch going forward.

In the human pharmaceuticals segment, expanding prescriptions for improved new drugs such as ONE-TOO tablet and increasing the number of large hospitals passing drug committee reviews could be key to a revenue recovery.

However, most of these plans are based on company statements and ongoing matters, and specific order outcomes or the timing of revenue recognition have not yet been confirmed through disclosure.